CN106367511A - Application of lncRNA-LOC100507195 in mycobacterium tuberculosis negative pulmonary tuberculosis diagnosis - Google Patents

Application of lncRNA-LOC100507195 in mycobacterium tuberculosis negative pulmonary tuberculosis diagnosis Download PDF

Info

Publication number
CN106367511A
CN106367511A CN201610833004.7A CN201610833004A CN106367511A CN 106367511 A CN106367511 A CN 106367511A CN 201610833004 A CN201610833004 A CN 201610833004A CN 106367511 A CN106367511 A CN 106367511A
Authority
CN
China
Prior art keywords
diagnosis
tuberculosis
pulmonary tuberculosis
lncrna
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201610833004.7A
Other languages
Chinese (zh)
Inventor
马骊
杨晓帆
温茜
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Southern Medical University
Original Assignee
Southern Medical University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Southern Medical University filed Critical Southern Medical University
Publication of CN106367511A publication Critical patent/CN106367511A/en
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/178Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The invention discloses application of lncRNA-LOC100507195 in mycobacterium tuberculosis negative pulmonary tuberculosis diagnosis. It is found that after MTB is infected with macrophage, consequently LOC100507195 expression is up-regulated. The detection results on the PBMC of 30 mycobacterium tuberculosis negative pulmonary tuberculosis patients show that the expression level of LOC100507195 is remarkably lower than that of a healthy volunteer; LOC100507195 is possibly adopted as an antituberculous protective factor of the macrophage, the expression of LOC100507195 is down-regulated, and consequently the body is likely to be infected with tuberculosis. The receiver operating characteristic curve analysis result shows that LOC100507195 is expected to become a new target spot of mycobacterium tuberculosis negative pulmonary tuberculosis diagnosis. Uninfected people and the mycobacterium tuberculosis negative pulmonary tuberculosis patients can be effectively distinguished by detecting the expression level of LOC100507195.

Description

Application in bacterium the moon diagnosis of pulmonary tuberculosis for the lncrna-loc100507195
Technical field
Present invention relates particularly to application in bacterium the moon diagnosis of pulmonary tuberculosis for the lncrna-loc100507195.
Background technology
Tuberculosis are still infection rate highest infectious disease in global range so far, prevention and control situation very severe.Quickly, sensitive Diagnosis is to improve therapeutic effect, the key of effective control transmission of tuberculosis.In national lunger, bacterium the moon lunger Account for the 60%~70% of active tuberculosiss patient, and the clinical symptoms of other pulmonary disease multiple and Features be difficult to Tuberculosis distinguish.The method of bacterium the moon pulmonary tuberculosis efficient diagnosis is lacked, often results in patient diagnosis delay or mistaken diagnosis.Though China Formulate some standards of diagnosis, but still suffer from many puzzlements in clinical practice, and unresolved efficient diagnosis bacterium the moon pulmonary tuberculosis This difficult problem.Therefore, find bacterium the moon diagnosis of pulmonary tuberculosis new logo, start new diagnostic method and become the task of top priority!
Existing diagnosis of pulmonary tuberculosis method is mainly sputum examination for tubercle bacillus, tuberculin test, its specific antibody determination, image Learn the methods such as inspection.Time-consuming for sputum examination for tubercle bacillus, and false negative is high;Tuberculin test false positive is high to be inoculated it is not easy to distinguish Bacillus calmette-guerin vaccine crowd and tuberculosis crowd;Imaging examination is difficult to differentiate between pulmonary tuberculosis and other pulmonary disease.And find nucleic acid and make For diagnosis marker, pcr technology is used as diagnostic method, has the advantages that quick, sensitive, and price compares specific antibody Cheaply, prepare and detection operation is also convenient for.Therefore, finding can be non-as the nucleic acids marker of bacterium the moon diagnosis of pulmonary tuberculosis, meaning All.
Mycobacterium tuberculosis (mycobacterium tuberculosis, mtb) belong to intracellular bacterial parasite, main parasitic in Macrophage (macrophage).Mycobacterium tuberculosis in the form of an aerosol, enter lung tissue through human respiratory tract, by alveolar Macrophage phagocytic (am), but mtb escapes the removing of body immune system by corresponding mechanism, and mtb will not be completely clear by am Remove.Therefore mtb can be in macrophage intracellular growth and breeding, and migrating by macrophage, and other are not infected to continue infection Macrophage.Lncrna (long noncoding rna) is the rna of the not encoding proteins that a class length is more than 200nt, Lncrna can be on epigenetic, regulate and control gene expression on transcription and post-transcriptional level, and its function extensively, participates in regulation and control body Various vital movements.Document has been had to prove, lncrna participates in the regulation and control of immunity of organism.
There is document report at present, lncrna can be used as cancer diagnosis mark.But not yet have using lncrna as The phthisical report of diagnostic markers analyte detection.
Content of the invention
It is an object of the invention to provide a kind of brand-new lncrna diagnosis marker loc100507195, for quickly examining Disconnected bacterium the moon pulmonary tuberculosis, and price is cheaper than current diagnostic method.
The technical solution used in the present invention is:
Application in Diagnosis of Tuberculosis for the lncrna nucleic acids marker, the nucleotide sequence of this lncrna nucleic acids marker is such as Shown in seq id no:1, it is designated as loc100507195.
Preferably, described Diagnosis of Tuberculosis is diagnosis of pulmonary tuberculosis.
Preferably, described diagnosis of pulmonary tuberculosis is bacterium the moon diagnosis of pulmonary tuberculosis.
A kind of bacterium the moon diagnosis of pulmonary tuberculosis test kit, this test kit contains can be to the expression of lncrna-loc100507195 Amount carries out quantitative reagent.
Diagnosis of pulmonary tuberculosis examination prepared by the reagent that the expression of lncrna-loc100507195 can be carried out with detection by quantitative Application in agent box.
Preferably, the reagent of described detection by quantitative contains and can detect lncrna-loc100507195 by real time fluorescent quantitative Primer sequence.
Preferably, described pulmonary tuberculosis are bacterium the moon pulmonary tuberculosis.
The invention has the beneficial effects as follows:
The batch screening by early stage for the present invention, the loc100507195 therefrom screening acquisition examines as bacterium the moon is phthisical Disconnected mark, by detecting the expression of loc100507195, can effectively be distinguished the crowd of being uninfected by and be suffered from bacterium the moon pulmonary tuberculosis Person.
Present invention discover that: after mtb infection macrophage, cause the various reactions of macrophage, turning including gene Record and the synthesis of albumen, the expression of lncrna is also regulated and controled.After mtb infection macrophage, can cause loc100507195's Up-regulated, illustrates that loc100507195 plays corresponding effect during mtb infection macrophage.Use fluorescent quantitation Pcr (qpcr) detects bacterium the moon pulmonary tuberculosis patient and the pbmc of healthy normal person, with respect to the pbmc of healthy normal person, Loc100507195 is but to lower in bacterium the moon pulmonary tuberculosis patient pbmc expression, and both have significant difference, and this is probably Loc100507195, as the antiphthisic protective factors of macrophage, its down-regulated expression, leads to body susceptible to tuberculosis.Therefore Loc100507195 can be used as the diagnosis marker of diagnosis bacterium the moon pulmonary tuberculosis patient and healthy normal person.
Brief description
Fig. 1 detects the expression of loc100507195 in the m φ of mtb infection for real time fluorescent quantitative pcr;
Fig. 2 detects the table of lncrna-loc100507195 in bacterium the moon lunger pbmc for real time fluorescent quantitative pcr Reach;
Fig. 3 is roc tracing analysiss.
Specific embodiment
Present invention discover that: 1. lead to loc100507195 up-regulated after mtb infection m φ;2. to 30 bacterium the moon pulmonary tuberculosis The testing result of patient pbmc then shows, the expression of its loc100507195 is substantially less than healthy volunteer;Experimenter's work Make characteristic curve (receiver operating characteristic curve, abbreviation roc curve) analysis result to show, Loc100507195 is expected to become bacterium the moon diagnosis of pulmonary tuberculosis novel targets.
With reference to specific embodiment, the present invention is described further, but is not limited thereto.
The up-regulated of loc100507195 in the m φ of embodiment 1 infection mtb
The pbmc of separating health volunteer, immunological magnetic bead sorting cd14+Mononuclear cell, with gm-csf induced monocyte to M φ breaks up, and the m φ of gained is infected mtb.After 72h, real time fluorescent quantitative pcr detects the expression water of loc100507195 in m φ Flat.
Testing result is as shown in figure 1, there it can be seen that the expression of the loc100507195 of mtb metainfective m φ Substantially raise, illustrate that mtb infection promotes the expression of loc100507195.
Embodiment 2 real time fluorescent quantitative pcr detects the expression of loc100507195 in bacterium the moon lunger pbmc
Extract the rna of 30 bacterium the moon lungers and 32 healthy volunteer pbmc, real time fluorescent quantitative pcr detects The expression of lncrna-loc100507195.
Testing result as shown in Fig. 2 there it can be seen that bacterium the moon lunger pbmc in loc100507195 expression be in Now notable down regulation trend (p < 0.001).
Embodiment 3loc100507195 is as the novel targets of bacterium the moon diagnosis of pulmonary tuberculosis
The study find that, compared with Healthy People, loc100507195 express in tubercular pbmc present extremely notable under Tune trend (p < 0.001).In order to understand loc100507195 pbmc expression change whether can be used for distinguish Healthy People with Tubercular, using roc tracing analysiss loc100507195, whether the expression change in pbmc examines for lungy for we Disconnected.
According to relative expression quantity in Healthy People and tubercular pbmc for the loc100507195, soft using statistical analysiss Part, set up abscissa be specificity, vertical coordinate be sensitivity roc curve, see Fig. 3.Result shows, roc area under curve auc A ()=0.8594, illustrates that loc100507195 has higher accuracy (Fig. 3) for tuberculosis patient diagnosis.A in roc curve Value meaning explanation: in a > in the case of 0.5, a is closer to 1, illustrates that diagnosis effect is better.A has relatively low standard when 0.5~0.7 Really property, has certain accuracy when 0.7~0.9, has high accuracy when more than 0.9.
Roc curve (cumulative frequency distribution) is analyzed, the results are shown in Table 1.
Table 1roc tracing analysiss result
(above ellipsis represents that initial data is too many, only lists critical data in table).
Table 1 interpretation of result is found: when transcriptional level cut-off value (thresholding) of loc100507195 takes 7.368, about Mounting index (youden ' s indx, yi) maximum (yi=62.5), now detection sensitivity can reach 81.25%, and specificity Reach 81.25%.So, it is feasible that loc100507195 is used for diagnosis lungy, for raising diagnosis lungy Rate is significant.
In sum: lncrna-loc100507195 can be used as bacterium the moon diagnosis of pulmonary tuberculosis novel targets.
Above-described embodiment is the present invention preferably embodiment, but embodiments of the present invention are not subject to above-described embodiment Limit, other any spirit without departing from the present invention and the change made under principle, modification, replacement, combine, simplify, All should be equivalent substitute mode, be included within protection scope of the present invention.
<110>Nanfang Medical Univ
<120>application in bacterium the moon diagnosis of pulmonary tuberculosis for the lncrna-loc100507195
<130>
<160> 1
<170> patentin version 3.5
<210> 1
<211> 574
<212> rna
<213>people (homo sapiens)
<400> 1
gagaggctgt ggcaagggtc catgcctgaa tgtgtagaac aagaacagct ggaggctgtg 60
gctttctcca ggaagaggtt tctaaatctg cctcttagaa gatatcagaa agttaaagtt 120
tctcttgctg ccgccgtgta agaaggacct tttgcctccc accatgattc taagtcctcc 180
ccagccacgt ggaactgctt tcatttggtc tcttttcgaa tcagaagacc cagaaaactt 240
ggatccactt ctggctctca tccctctggg cagtgtgatt tggattgagc agatgctccg 300
gctgccactc catcatatat tggaaacagc attactttat agtaaatcat gaccacggtg 360
tatggcaatg aagttgcatc tgaagcagcc ggcaccctat gtgctagctg gcttttagac 420
caggagactg tgaatctgtg gtcaggatct ctttagggct gctaaatata tactacccac 480
tatcactcgc tggagctgca gaccctagtt ttagagtttc acttcttaaa gaccttcatc 540
cttattaaaa tggtaatatc cttactgtca tcaa 574

Claims (7)

  1. Application in Diagnosis of Tuberculosis for the 1.lncrna nucleic acids marker it is characterised in that: the nucleoside of this lncrna nucleic acids marker Acid sequence, as shown in seq id no:1, is designated as loc100507195.
  2. 2. according to claim 1 application it is characterised in that: described Diagnosis of Tuberculosis be diagnosis of pulmonary tuberculosis.
  3. 3. according to claim 2 application it is characterised in that: described diagnosis of pulmonary tuberculosis be bacterium the moon diagnosis of pulmonary tuberculosis.
  4. 4. a kind of bacterium the moon diagnosis of pulmonary tuberculosis test kit it is characterised in that: this test kit contains can be to lncrna- The expression of loc100507195 carries out quantitative reagent.
  5. 5. diagnosis of pulmonary tuberculosis reagent prepared by the reagent that the expression of lncrna-loc100507195 can be carried out with detection by quantitative Application in box.
  6. 6. application according to claim 5 it is characterised in that: the reagent of described detection by quantitative contain can real-time fluorescence fixed The primer sequence of amount detection lncrna-loc100507195.
  7. 7. according to claim 5 application it is characterised in that: described pulmonary tuberculosis be bacterium the moon pulmonary tuberculosis.
CN201610833004.7A 2016-03-16 2016-09-19 Application of lncRNA-LOC100507195 in mycobacterium tuberculosis negative pulmonary tuberculosis diagnosis Pending CN106367511A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201610151024 2016-03-16
CN2016101510246 2016-03-16

Publications (1)

Publication Number Publication Date
CN106367511A true CN106367511A (en) 2017-02-01

Family

ID=57896903

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201610833004.7A Pending CN106367511A (en) 2016-03-16 2016-09-19 Application of lncRNA-LOC100507195 in mycobacterium tuberculosis negative pulmonary tuberculosis diagnosis

Country Status (1)

Country Link
CN (1) CN106367511A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111304313A (en) * 2019-12-13 2020-06-19 南方医科大学 Application of reagent for detecting FPR1 gene expression level

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KIMURA K.等: "登录号NR_120458.1", 《NCBI_GENBANK》 *
ZHENGJUN YI等: "Identifcation of differentially expressed long non-coding RNAs in CD4+ T cells response to latent tuberculosis infection", 《JOURNAL OF INFECTION》 *
王天齐等: "结核分枝杆菌相关非编码RNA研究进展", 《中国奶牛》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111304313A (en) * 2019-12-13 2020-06-19 南方医科大学 Application of reagent for detecting FPR1 gene expression level

Similar Documents

Publication Publication Date Title
CN109280713A (en) For detecting the method and kit of cell-free pathogen specific nucleic acid
CN110295229A (en) Application of the PRDM1 as marker in preparation diagnostic activities product lungy
Zheng et al. Epstein-Barr virus mir-bart1-5p detection via nasopharyngeal brush sampling is effective for diagnosing nasopharyngeal carcinoma
CN110205378B (en) Vertebral column tuberculosis plasma miRNA combined diagnosis marker and application thereof
CN109913564B (en) Primer probe composition, kit and method for detecting chlamydia pneumoniae
CN109825571A (en) Depression detects biomarker and its kit
Addissouky Detecting liver fibrosis by recent reliable biomarkers in viral hepatitis patients
Mushtaq et al. Comparison of chitinase-3-like protein 1, aspartate aminotransferase-to-platelet ratio index, and fibrosis-4 index with shear-wave elastography
JP5805518B2 (en) Multiplex colorectal cancer marker panel
CN106367511A (en) Application of lncRNA-LOC100507195 in mycobacterium tuberculosis negative pulmonary tuberculosis diagnosis
CN104561277A (en) Target sequence for detecting mycoplasma pneumoniae and detection kit
CN105400870B (en) Applications of the CD1c in bacterium the moon diagnosis of pulmonary tuberculosis
CN116949161A (en) Group of tuberculosis serum exosome miRNA markers and application thereof
CN106480176A (en) Application of the lncRNA MIR3945HG V1 in bacterium the moon diagnosis of pulmonary tuberculosis
CN106520916A (en) Applications of lncRNA-MIR3945HG V2 in diagnosis of mycobacterium tuberculosis negative pulmonary tuberculosis
CN103882133A (en) Primer pair for detecting ureaplasma urealyticum, kit and application thereof
CN105316428A (en) Method for detecting human cytomegalovirns PP65 genes and kit
CN110527721B (en) Old tuberculosis marker and application thereof
CN108504736A (en) Detect application of the system of ORM1 gene expression amounts in diagnosis of tuberculosis
CN113755614A (en) Rapid high-sensitivity differential diagnosis kit for Brucella vaccine strain and wild strain and use method thereof
CN108950019A (en) The Real-time PCR specific primer and probe and detection kit and detection method of liver gregarina
CN111534611A (en) Fluorescent quantitative PCR method for detecting toxigenic streptococcus suis and corresponding kit
Ali Novel approaches to diagnose COVID-19
CN104805215B (en) People is with the method for quick of Brucella sp attenuated vaccine strain 104M
CN116047082B (en) Application of FGL1 protein in preparing kit for diagnosing chronic kidney disease

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination